secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001619856-26-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q1 2026 rev flat at $2.4M; FDA aligns on pivotal trial for vispa-cel
----------------------------------------------------------------------------

- FDA alignment on ANTLER-3 pivotal phase 3 trial for vispa-cel in 2L LBCL; primary endpoint PFS, crossover allowed.
- Cash and marketable securities $118.6M as of Mar 31, 2026; expected to fund into 2H 2027.
- R&D expenses down to $20.6M from $35.5M; G&A down to $8.1M from $9.7M YoY.
- CB-011 granted RMAT for r/r MM; enrollment ongoing, dose expansion data expected 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000035/0001619856-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000035/crbu-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001619856-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer